ASLAN Pharmaceuticals

$1.65
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-2.66%) As of 1:44 PM EDT today

Why Robinhood?

You can buy or sell ASLN and other stocks, options, and ETFs commission-free!

About ASLN

ASLAN Pharmaceuticals Limited American Depositary Shares, also called ASLAN Pharmaceuticals, is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002. Read More The firm's portfolio focuses on validated growth pathways applied to new patient segments, novel immune checkpoints, and novel cancer metabolic pathways. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. The listed name for ASLN is ASLAN Pharmaceuticals Limited American Depositary Shares.

CEO
Carl Aslan Jason Morton Firth
Employees
Headquarters
Singapore, Central Singapore
Founded
2010
Market Cap
62.69M
Price-Earnings Ratio
Dividend Yield
Average Volume
1.12M
High Today
$1.67
Low Today
$1.60
Open Price
$1.67
Volume
36.89K
52 Week High
$8.18
52 Week Low
$0.35

Collections

ASLN Earnings

-$0.35
-$0.23
-$0.12
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 13, Pre-Market

You May Also Like